On September 2, 2026 Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ("Ascentage Pharma" or the "Company"), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, reported that the Company’s management will participate in four upcoming investor conferences in New York, New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 2026 Biopharma Back to School Conference
Format: Fireside chat and one-on-one investor meetings
Date and Time: Wednesday, September 9, 2026, 4:20 p.m. to 4:55 p.m. ET
Location: JW Marriott Essex House, 160 Central Park South, New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Format: Company presentation and one-on-one investor meetings
Date and Time: Monday, September 14, 2026, 9:00 a.m. to 9:30 a.m. ET
Location: Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY

Deutsche Bank 2026 Healthcare Summit
Format: Company presentation and one-on-one investor meetings
Date: Wednesday, September 16 – Thursday, September 17, 2026
Location: Deutsche Bank Center, One Columbus Circle, New York, NY

Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum
Format: Company presentation and one-on-one investor meetings
Date: Wednesday, September 23 – Thursday, September 24, 2026
Location: New York, NY

Investors interested in scheduling a meeting with the Ascentage Pharma management team should contact their conference representative.

(Press release, Ascentage Pharma, SEP 2, 2026, View Source [SID1234670566])

On September 2, 2026 Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported that CFO Raphi Levy will participate in the following investor conferences in September 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Citi’s 2026 Biopharma Back to School Conference
Format: 1×1 Meetings
Date: Wednesday, September 9, 2026
Location: New York, NY

Event: H.C. Wainwright 28th Annual Global Investor Conference
Format: Fireside Chat and 1×1 Meetings
Date: Monday, September 14, 2026
Time: 9:30 – 10:00AM ET
Location: New York, NY

Mr. Levy will be available for 1×1 investor meetings at all conferences. Please reach out to your Citi or H.C. Wainwright representatives to schedule.

(Press release, Alpha Tau Medical, SEP 2, 2026, View Source [SID1234670565])

On September 2, 2026 ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, reported that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the meetings are as follows:

Wells Fargo 21st Annual Healthcare Conference

Format: Fireside Chat and One-on-one Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA
Time of Fireside Chat Presentation: 3:45 PM ET
Webcast link: Available here

Cantor Global Healthcare Conference

Format: Fireside Chat and One-on-one Meetings
Date: Thursday, September 10, 2026
Location: New York, NY
Time of Fireside Chat Presentation: 10:20 AM ET
Webcast link: Available here

H.C. Wainwright 28th Annual Global Investment Conference

Format: Fireside Chat and One-on-one Meetings
Date: Monday, September 14, 2026
Location: New York, NY
Time of Fireside Chat Presentation: 1:30 PM ET
Webcast link: Available here

The webcasts of the fireside chats can be accessed through the links above or by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the Events and Presentations tab. Replays of the webcasts will be archived for up to 90 days following the presentation dates.

(Press release, ALX Oncology, SEP 2, 2026, View Source [SID1234670564])

On September 2, 2026 CG Oncology, Inc. (NASDAQ: CGON) reported that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Fitzgerald Global Healthcare Conference
Presentation Time: Wednesday, September 9, 2026 at 8:00am ET

Morgan Stanley Global Healthcare Conference
Presentation Time: Monday, September 14, 2026 at 4:50pm ET

Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company’s website at www.cgoncology.com. The webcast replays will be available shortly after the conclusion of the live presentations and archived for approximately 90 days.

(Press release, CG Oncology, SEP 2, 2026, View Source [SID1234670563])

On September 2, 2026 RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, reported that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Bagai and Mr. Voll will discuss RenovoRx’s record second quarter revenue, driven by increasing commercial demand for RenovoCath as a standalone drug-delivery device and strong repeat orders from existing customers at high-volume cancer centers. They will also highlight the first clinical use of RenovoCath in a patient diagnosed with sarcoma at commercial cancer center, CARTI Cancer Center Little Rock, demonstrating the potential for treatment across a broader range of solid tumors.

An update on the fully enrolled Phase III TIGeR-PaC trial will be provided by Mr. Bagai. Trial completion is expected in the first half of 2027, with initial top line data availability expected in the second half of 2027. TIGeR-PaC is evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath in patients with locally advanced pancreatic cancer (LAPC).

In August 2026, pharmacokinetic and pharmacodynamic (PK-PD) data from a sub-study of the TIGeR-PaC clinical trial published in the peer-reviewed journal Cancer Chemotherapy and Pharmacology showed that TAMP (Trans-Arterial Micro-Perfusion)-mediated delivery concentrated chemotherapy at the tumor site, extracting about 51% of the drug locally before it entered the bloodstream. A statistically significant correlation between local drug metabolism and lower CA 19-9 levels also suggested improved tumor penetration and a potential response to intra-arterial delivery. Additionally, this approach has the potential to meaningfully reduce systemic exposure and related side effects.

RenovoRx also continues to advance its oncology pipeline. Mr. Bagai will discuss the Company’s investigator-initiated trials (IITs) in borderline resectable and metastatic pancreatic cancer, along with its ongoing post-marketing registry study. These studies are expanding the clinical evidence base for RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) platform and may broaden the platform’s therapeutic reach.

H.C. Wainwright Conference Details
Dates: September 14-16, 2026
Presentation Date and Time: Monday, September 14 at 1:30 p.m. ET
Presentation Location: Louis (4th Floor)
Webcast: View Source

To schedule a one-on-one investor meeting with RenovoRx’s management team, please contact KCSA Strategic Communications at [email protected].

(Press release, Renovorx, SEP 2, 2026, https://www.globenewswire.com/news-release/2026/09/02/3355141/0/en/renovorx-to-present-at-h-c-wainwright-28th-annual-global-investment-conference-september-14th-16th.html [SID1234670562])